Invention Grant
US08445479B2 Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
有权
星形孢菌素衍生物作为FLT3受体酪氨酸激酶活性的抑制剂
- Patent Title: Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity
- Patent Title (中): 星形孢菌素衍生物作为FLT3受体酪氨酸激酶活性的抑制剂
-
Application No.: US13524340Application Date: 2012-06-15
-
Publication No.: US08445479B2Publication Date: 2013-05-21
- Inventor: James Douglas Griffin , Paul William Manley
- Applicant: James Douglas Griffin , Paul William Manley
- Applicant Address: CH Basel US MA Boston
- Assignee: Novartis AG,Dana-Farber-Cancer Institute Inc.
- Current Assignee: Novartis AG,Dana-Farber-Cancer Institute Inc.
- Current Assignee Address: CH Basel US MA Boston
- Agent George Dohmann
- Main IPC: A61P35/02
- IPC: A61P35/02 ; A61K31/55 ; A61K31/535 ; C07D498/22 ; C07D487/04 ; C07D487/14 ; C07D519/00
Abstract:
The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias and myelodysplastic syndromes, and to a method of treating diseases involving deregulated FLT3 receptor tyrosine kinase activity.
Public/Granted literature
- US20120252785A1 STAUROSPORINE DERIVATIVES AS INHIBITORS OF FLT3 RECEPTOR TYROSINE KINASE ACTIVITY Public/Granted day:2012-10-04
Information query
